SEVERE CORONAVIRUS DISEASE 2019 : FROM PATHOGENESIS TO THERAPY
Copyright © 2023 by the Shock Society..
ABSTRACT: The COVID-19 pandemic has been a challenge to propose efficient therapies. Because severe SARS-CoV2 infection is a viral sepsis eventually followed by an immunological autoinflammatory phenomenon, many approaches have been inspired by the previous attempts made in bacterial sepsis, while specific antiviral strategies (use of interferon or specific drugs) have been additionally investigated. We summarize our current thinking on the use of SARS-CoV-2 antivirals, corticosteroids, anti-IL-1, anti-IL-6, anti-C5a, as well as stem cell therapy in severe COVID-19. Patient stratification and appropriate time window will be important to be defined to guide successful treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Shock (Augusta, Ga.) - 59(2023), 3S Suppl 1 vom: 01. März, Seite 10-15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cavaillon, Jean-Marc [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/SHK.0000000000001956 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349821917 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349821917 | ||
| 003 | DE-627 | ||
| 005 | 20231226043538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/SHK.0000000000001956 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349821917 | ||
| 035 | |a (NLM)36469709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cavaillon, Jean-Marc |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SEVERE CORONAVIRUS DISEASE 2019 |b FROM PATHOGENESIS TO THERAPY |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the Shock Society. | ||
| 520 | |a ABSTRACT: The COVID-19 pandemic has been a challenge to propose efficient therapies. Because severe SARS-CoV2 infection is a viral sepsis eventually followed by an immunological autoinflammatory phenomenon, many approaches have been inspired by the previous attempts made in bacterial sepsis, while specific antiviral strategies (use of interferon or specific drugs) have been additionally investigated. We summarize our current thinking on the use of SARS-CoV-2 antivirals, corticosteroids, anti-IL-1, anti-IL-6, anti-C5a, as well as stem cell therapy in severe COVID-19. Patient stratification and appropriate time window will be important to be defined to guide successful treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Artigas, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Barratt-Due, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Giamarellos-Bourboulis, Evangelos J |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Hernando |e verfasserin |4 aut | |
| 700 | 1 | |a Hayem, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Vlaar, Alexander P J |e verfasserin |4 aut | |
| 700 | 1 | |a Wiersinga, W Joost |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Shock (Augusta, Ga.) |d 1996 |g 59(2023), 3S Suppl 1 vom: 01. März, Seite 10-15 |w (DE-627)NLM074735713 |x 1540-0514 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2023 |g number:3S Suppl 1 |g day:01 |g month:03 |g pages:10-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/SHK.0000000000001956 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2023 |e 3S Suppl 1 |b 01 |c 03 |h 10-15 | ||